Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

CSC-CAMS/PUMC-Oxford High level Innovative Talent Programme

This high-level medical innovative talent training programme, supported by the China Scholarship Council, Chinese Academy of Medical Sciences & Peking Union Medical College and the University of Oxford, which is referred to as the MD/PHD Scholarship Programme, is aimed at cultivating talented students to be interdisciplinary and innovative clinicians/scientists.

Find out more

COI prioritise funding support to the current crisis caused by novel coronavirus

Find out more

Tao Dong's group publish new research on Self-maintaining CD103+ cancer-specific T cells

Find out more

Latest News

COI prioritise funding support to the current crisis caused by novel coronavirus

COI Directors Professor Tao Dong and Xuetao Cao have prioritised funding support in response to the current crisis caused by nCoV 2019, supporting positive actions taken by the Medical Sciences Divisions and University of Oxford.

Visitors to COI from the Ministry of Science and Technology (MOST)

Delegates from the Ministry of Science and Technology and Chinese Embassy visited the CAMS Oxford Institute in December 2019.

Chinese Scholarship Council (CSC) - NDM - CAMS Oxford Institute (COI) Scholarship Interviews 2019

The CSC-CAMS/PUMC Oxford High-level Innovative Talent Scholarships and CSC-NDM Scholarships Interviews were held in Beijing in November 2019, representatives from the University of Oxford, the Chinese Academy of Medical Sciences (CAMS) and the Chinese Scholarship Council (CSC) were present.

Tao Dong's group publish new research on Self-maintaining CD103+ cancer-specific T cells

A new research discovered circulating antigen-specific CD103+CD8+ T cells can self-regulate their CD103 expression via production of active TGFβ1 and have better TCR signalling and effector function compared to CD103- populations.

More News